Clinical trials
Phase 4 Mood Disorders trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2019 | 3 |
| 2022 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Terminated | 3 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of North Carolina, Chapel Hill | 3 |
| Icahn School of Medicine at Mount Sinai | 2 |
| National Institute of Mental Health (NIMH) | 2 |
| Stanford University | 2 |
| Boston Medical Center | 1 |
| Joliet Center for Clinical Research | 1 |
| Massachusetts General Hospital | 1 |
| Medical University of South Carolina | 1 |
| New York State Psychiatric Institute | 1 |
| US Department of Veterans Affairs | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mood Disorders | 19 |
| Depressive Disorder | 5 |
| Major Depressive Disorder | 4 |
| Bipolar Disorder | 3 |
| Mental Disorders | 3 |
| Anxiety Disorders | 2 |
| Cognitive Dysfunction | 2 |
| Insulin Resistance | 2 |
| Psychotic Disorders | 2 |
| Substance-Related Disorders | 2 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.